(Total Views: 825)
Posted On: 05/22/2020 10:50:58 PM
Post# of 153929
Regarding a potential cancer BTD, including the preliminary (post-liminary) meeting with the FDA, I think it is worth revisiting this excerpt from CytoDyn's filings:
This is a hair-on-fire time for CytoDyn, and the next two months will likely be no calmer than the last two months. With global delays of clinical trials due to COVID, and the lingering question regarding how the FDA will treat months of missing labs and imaging data proving efficacy, this date may very well pass without a BTD having been granted -- unless the board agrees to extend the deadline due to unforeseeable circumstances.
Quote:That means, this incentive bump sunsets on July 28, 2020, just about two months from now.
On January 28, 2020, the Company awarded 11,650,000 performance shares to certain of its directors and executive officers outside of the 2012 Plan. The awards will vest and be settled in shares of common stock of the Company if the Company achieves FDA Breakthrough Therapy designation for cancer within 6 months of the award date and if certain other requirements have been met
This is a hair-on-fire time for CytoDyn, and the next two months will likely be no calmer than the last two months. With global delays of clinical trials due to COVID, and the lingering question regarding how the FDA will treat months of missing labs and imaging data proving efficacy, this date may very well pass without a BTD having been granted -- unless the board agrees to extend the deadline due to unforeseeable circumstances.
(2)
(0)
